HRP20120337T1 - Korištenje seleno-kvasaca u liječenju alzheimerove bolesti - Google Patents

Korištenje seleno-kvasaca u liječenju alzheimerove bolesti Download PDF

Info

Publication number: HRP20120337T1
Authority: HR; Croatia
Prior art keywords: naugalube; selenium; cathepsin; gene; disease
Prior art date: 2005-10-14

Application number

HRP20120337TT

Other languages

English (en)

Croatian (hr)

Inventor

Pearse Lyons Thomas

Power Ronan

Original Assignee

Alltech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-14

Filing date

2012-04-16

Publication date

2012-05-31

2012-04-16 Application filed by Alltech filed Critical Alltech

2012-05-31 Publication of HRP20120337T1 publication Critical patent/HRP20120337T1/hr

Links

BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract 24
239000011669 selenium Substances 0.000 title claims abstract 24
229910052711 selenium Inorganic materials 0.000 title claims abstract 24
208000024827 Alzheimer disease Diseases 0.000 title claims 8
240000004808 Saccharomyces cerevisiae Species 0.000 title claims 7
108090000623 proteins and genes Proteins 0.000 claims abstract 7
239000000203 mixture Substances 0.000 claims abstract 5
230000001225 therapeutic effect Effects 0.000 claims abstract 5
229940091258 selenium supplement Drugs 0.000 claims 20
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 12
XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical class C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 claims 6
-1 alkylidene bisphenols Chemical class 0.000 claims 6
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 6
239000003814 drug Substances 0.000 claims 6
229910052751 metal Inorganic materials 0.000 claims 6
239000002184 metal Substances 0.000 claims 6
229940079593 drug Drugs 0.000 claims 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 4
239000004322 Butylated hydroxytoluene Substances 0.000 claims 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 4
VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims 4
239000003963 antioxidant agent Substances 0.000 claims 4
230000003078 antioxidant effect Effects 0.000 claims 4
235000006708 antioxidants Nutrition 0.000 claims 4
235000010323 ascorbic acid Nutrition 0.000 claims 4
229960005070 ascorbic acid Drugs 0.000 claims 4
239000011668 ascorbic acid Substances 0.000 claims 4
235000010354 butylated hydroxytoluene Nutrition 0.000 claims 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 4
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
229940124596 AChE inhibitor Drugs 0.000 claims 3
229940099433 NMDA receptor antagonist Drugs 0.000 claims 3
239000002253 acid Substances 0.000 claims 3
239000013522 chelant Substances 0.000 claims 3
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 3
108090000765 processed proteins & peptides Proteins 0.000 claims 3
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims 2
NVXKDTVBVPMPAL-UHFFFAOYSA-N 1,2,2-trimethylquinoline Chemical class C1=CC=C2C=CC(C)(C)N(C)C2=C1 NVXKDTVBVPMPAL-UHFFFAOYSA-N 0.000 claims 2
150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims 2
102000012440 Acetylcholinesterase Human genes 0.000 claims 2
108010022752 Acetylcholinesterase Proteins 0.000 claims 2
102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims 2
108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims 2
229930185605 Bisphenol Natural products 0.000 claims 2
TUSUWHFYKZZRIG-JQWMYKLHSA-N C([C@@H](NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@H](CC(C)C)C(N)=O)C1=CC=CC=C1 Chemical compound C([C@@H](NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@H](CC(C)C)C(N)=O)C1=CC=CC=C1 TUSUWHFYKZZRIG-JQWMYKLHSA-N 0.000 claims 2
102000004225 Cathepsin B Human genes 0.000 claims 2
108090000712 Cathepsin B Proteins 0.000 claims 2
102000003908 Cathepsin D Human genes 0.000 claims 2
108090000258 Cathepsin D Proteins 0.000 claims 2
102100024940 Cathepsin K Human genes 0.000 claims 2
101710177066 Cathepsin O Proteins 0.000 claims 2
102000011937 Cathepsin Z Human genes 0.000 claims 2
108010061117 Cathepsin Z Proteins 0.000 claims 2
108010084457 Cathepsins Proteins 0.000 claims 2
QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical group C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 2
239000005749 Copper compound Substances 0.000 claims 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 2
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 2
102000010445 Lactoferrin Human genes 0.000 claims 2
108010063045 Lactoferrin Proteins 0.000 claims 2
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 2
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims 2
QAPVYZRWKDXNDK-UHFFFAOYSA-N P,P-Dioctyldiphenylamine Chemical compound C1=CC(CCCCCCCC)=CC=C1NC1=CC=C(CCCCCCCC)C=C1 QAPVYZRWKDXNDK-UHFFFAOYSA-N 0.000 claims 2
108010050254 Presenilins Proteins 0.000 claims 2
241000241413 Propolis Species 0.000 claims 2
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
244000269722 Thea sinensis Species 0.000 claims 2
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
229930003268 Vitamin C Natural products 0.000 claims 2
229930003427 Vitamin E Natural products 0.000 claims 2
235000009754 Vitis X bourquina Nutrition 0.000 claims 2
235000012333 Vitis X labruscana Nutrition 0.000 claims 2
240000006365 Vitis vinifera Species 0.000 claims 2
235000014787 Vitis vinifera Nutrition 0.000 claims 2
CGRTZESQZZGAAU-UHFFFAOYSA-N [2-[3-[1-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoyloxy]-2-methylpropan-2-yl]-2,4,8,10-tetraoxaspiro[5.5]undecan-9-yl]-2-methylpropyl] 3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C)=CC(CCC(=O)OCC(C)(C)C2OCC3(CO2)COC(OC3)C(C)(C)COC(=O)CCC=2C=C(C(O)=C(C)C=2)C(C)(C)C)=C1 CGRTZESQZZGAAU-UHFFFAOYSA-N 0.000 claims 2
229940022698 acetylcholinesterase Drugs 0.000 claims 2
229960004308 acetylcysteine Drugs 0.000 claims 2
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 2
229940087168 alpha tocopherol Drugs 0.000 claims 2
239000000427 antigen Substances 0.000 claims 2
102000036639 antigens Human genes 0.000 claims 2
108091007433 antigens Proteins 0.000 claims 2
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 2
235000010385 ascorbyl palmitate Nutrition 0.000 claims 2
235000013734 beta-carotene Nutrition 0.000 claims 2
239000011648 beta-carotene Substances 0.000 claims 2
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 2
229960002747 betacarotene Drugs 0.000 claims 2
229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
235000017471 coenzyme Q10 Nutrition 0.000 claims 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 2
230000000295 complement effect Effects 0.000 claims 2
150000001880 copper compounds Chemical class 0.000 claims 2
239000012990 dithiocarbamate Substances 0.000 claims 2
150000004659 dithiocarbamates Chemical class 0.000 claims 2
229960003530 donepezil Drugs 0.000 claims 2
150000002170 ethers Chemical class 0.000 claims 2
229960003980 galantamine Drugs 0.000 claims 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 2
235000006539 genistein Nutrition 0.000 claims 2
229940045109 genistein Drugs 0.000 claims 2
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 2
235000009569 green tea Nutrition 0.000 claims 2
229930013032 isoflavonoid Natural products 0.000 claims 2
150000003817 isoflavonoid derivatives Chemical class 0.000 claims 2
235000012891 isoflavonoids Nutrition 0.000 claims 2
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 2
229940078795 lactoferrin Drugs 0.000 claims 2
235000021242 lactoferrin Nutrition 0.000 claims 2
239000001751 lycopene Substances 0.000 claims 2
235000012661 lycopene Nutrition 0.000 claims 2
229960004999 lycopene Drugs 0.000 claims 2
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 2
229960004640 memantine Drugs 0.000 claims 2
FSWDLYNGJBGFJH-UHFFFAOYSA-N n,n'-di-2-butyl-1,4-phenylenediamine Chemical compound CCC(C)NC1=CC=C(NC(C)CC)C=C1 FSWDLYNGJBGFJH-UHFFFAOYSA-N 0.000 claims 2
108700022821 nicastrin Proteins 0.000 claims 2
150000002989 phenols Chemical class 0.000 claims 2
150000004986 phenylenediamines Chemical class 0.000 claims 2
235000010204 pine bark Nutrition 0.000 claims 2
229920001184 polypeptide Polymers 0.000 claims 2
102000004196 processed proteins & peptides Human genes 0.000 claims 2
229940069949 propolis Drugs 0.000 claims 2
SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical class C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 claims 2
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 2
235000021283 resveratrol Nutrition 0.000 claims 2
229940016667 resveratrol Drugs 0.000 claims 2
235000020944 retinol Nutrition 0.000 claims 2
229960003471 retinol Drugs 0.000 claims 2
239000011607 retinol Substances 0.000 claims 2
229940108325 retinyl palmitate Drugs 0.000 claims 2
235000019172 retinyl palmitate Nutrition 0.000 claims 2
239000011769 retinyl palmitate Substances 0.000 claims 2
229960004136 rivastigmine Drugs 0.000 claims 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 2
229940001584 sodium metabisulfite Drugs 0.000 claims 2
235000010262 sodium metabisulphite Nutrition 0.000 claims 2
229960001685 tacrine Drugs 0.000 claims 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
229960000984 tocofersolan Drugs 0.000 claims 2
229930003799 tocopherol Natural products 0.000 claims 2
239000011732 tocopherol Substances 0.000 claims 2
125000002640 tocopherol group Chemical class 0.000 claims 2
235000019149 tocopherols Nutrition 0.000 claims 2
229930003802 tocotrienol Natural products 0.000 claims 2
239000011731 tocotrienol Substances 0.000 claims 2
229940068778 tocotrienols Drugs 0.000 claims 2
235000019148 tocotrienols Nutrition 0.000 claims 2
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims 2
229940035936 ubiquinone Drugs 0.000 claims 2
235000019155 vitamin A Nutrition 0.000 claims 2
239000011719 vitamin A Substances 0.000 claims 2
235000019154 vitamin C Nutrition 0.000 claims 2
239000011718 vitamin C Substances 0.000 claims 2
235000019165 vitamin E Nutrition 0.000 claims 2
239000011709 vitamin E Substances 0.000 claims 2
229940046009 vitamin E Drugs 0.000 claims 2
229940045997 vitamin a Drugs 0.000 claims 2
235000004835 α-tocopherol Nutrition 0.000 claims 2
239000002076 α-tocopherol Substances 0.000 claims 2
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 2
IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims 1
101150052939 APBA1 gene Proteins 0.000 claims 1
102100036439 Amyloid beta precursor protein binding family B member 1 Human genes 0.000 claims 1
101000928670 Homo sapiens Amyloid beta precursor protein binding family B member 1 Proteins 0.000 claims 1
108010041081 Kv Channel-Interacting Proteins Proteins 0.000 claims 1
102000000254 Kv Channel-Interacting Proteins Human genes 0.000 claims 1
229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
102000015499 Presenilins Human genes 0.000 claims 1
GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
210000003710 cerebral cortex Anatomy 0.000 claims 1
230000007423 decrease Effects 0.000 claims 1
DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical class C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims 1
229930003944 flavone Natural products 0.000 claims 1
150000002212 flavone derivatives Chemical class 0.000 claims 1
235000011949 flavones Nutrition 0.000 claims 1
229930003935 flavonoid Natural products 0.000 claims 1
235000017173 flavonoids Nutrition 0.000 claims 1
150000002215 flavonoids Chemical class 0.000 claims 1
239000003112 inhibitor Substances 0.000 claims 1
102000046701 nicastrin Human genes 0.000 claims 1
230000001575 pathological effect Effects 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
229960001471 sodium selenite Drugs 0.000 claims 1
235000015921 sodium selenite Nutrition 0.000 claims 1
239000011781 sodium selenite Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 claims 1
VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract 2
RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 abstract 1
RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
230000003915 cell function Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
229960002718 selenomethionine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HRP20120337TT 2005-10-14 2012-04-16 Korištenje seleno-kvasaca u liječenju alzheimerove bolesti HRP20120337T1 (hr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US72692205P	2005-10-14	2005-10-14
US72701805P	2005-10-14	2005-10-14
US72701505P	2005-10-14	2005-10-14
US72695105P	2005-10-14	2005-10-14

Publications (1)

Publication Number	Publication Date
HRP20120337T1 true HRP20120337T1 (hr)	2012-05-31

Family

ID=35734026

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20120337TT HRP20120337T1 (hr)	2005-10-14	2012-04-16	Korištenje seleno-kvasaca u liječenju alzheimerove bolesti

Country Status (14)

Country	Link
EP (5)	EP1774972B1 (zh)
JP (1)	JP4753683B2 (zh)
CN (2)	CN102764279B (zh)
AT (1)	ATE547107T1 (zh)
AU (1)	AU2005227420B2 (zh)
CY (1)	CY1112790T1 (zh)
DK (2)	DK1779858T3 (zh)
ES (2)	ES2382334T3 (zh)
HR (1)	HRP20120337T1 (zh)
PL (2)	PL1779858T3 (zh)
PT (2)	PT1779858E (zh)
RS (2)	RS52257B (zh)
SI (1)	SI1774972T1 (zh)
TW (1)	TWI319708B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5542430B2 (ja) *	2006-03-29	2014-07-09	ベラコルセラピューティクスプロプライエタリーリミテッド	神経変性疾患の治療
JP5616631B2 (ja) *	2006-04-24	2014-10-29	オルテックインコーポレイテッド	細胞機能を変化させるための方法および組成物
EP2698166B1 (en)	2006-10-10	2015-09-30	Regenesance B.V.	Complement inhibition for improved nerve regeneration
US7696251B2 (en)	2007-02-12	2010-04-13	Incorporated National University Iwate University	Method for inhibiting neuronal cell death induced by oxidative glutamate toxicity
WO2008119109A1 (en) *	2007-03-29	2008-10-09	Velacor Therapeutics Pty Ltd	Treatment of neurological disorders
US8598150B1 (en)	2008-04-02	2013-12-03	Jonathan R. Brestoff	Composition and method for affecting obesity and related conditions
US8987245B2 (en)	2008-04-02	2015-03-24	Jonathan R. Brestoff Parker	Composition and method for affecting obesity and related conditions
EP2459742B1 (en) *	2009-07-29	2016-04-06	Pharnext	New diagnostic tools for alzheimer disease
ES2441974T3 (es) *	2009-08-26	2014-02-07	Milmed Ab	Composición para el tratamiento de enfermedades o trastornos neurodegenerativos, método y uso que comprende levadura electromagnéticamente irradiada
US8263752B2 (en) *	2010-03-18	2012-09-11	Alltech, Inc.	Methods for separating soluble selenoglycoproteins
WO2012095548A2 (es) *	2011-01-13	2012-07-19	Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned)	Compuestos para el tratamiento de enfermedades neurodegenerativas
SG11201507061XA (en) *	2013-03-15	2015-10-29	Alltech Inc	Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
KR102321320B1 (ko) *	2013-07-09	2021-11-03	애넥슨, 인코포레이티드	항-보체 인자 ｃ１ｑ 항체 및 이의 용도
CN103848898B (zh) *	2014-02-17	2016-01-27	南昌大学	双酚A的抗原模拟表位Ph3及其应用
HUE051713T2 (hu) *	2014-03-14	2021-03-29	Alltech Inc	Szelenoorganikus vegyületeket tartalmazó készítmények és ezek alkalmazása
JP6951246B2 (ja)	2014-11-05	2021-10-20	アネクソン，インコーポレーテッド	ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
CN104825498A (zh) *	2015-03-30	2015-08-12	安徽省华信生物药业股份有限公司	硒酵母在阿尔茨海默病防治中的应用
WO2017048252A1 (en) *	2015-09-15	2017-03-23	Alltech, Inc.	Compositions of selenoorganic compounds and methods of use thereof
CN115260310A (zh)	2015-11-24	2022-11-01	安尼艾克松股份有限公司	抗补体因子c1q的fab片段及其应用
WO2017096049A1 (en)	2015-12-03	2017-06-08	The University Of North Carolina At Pembroke	Materials for cathepsin b enhancement and methods of use
EP4379376A3 (en) *	2017-09-07	2024-07-17	The Children's Hospital Of Philadelphia	Compositions and methods for treatment of hereditary cystatin c amyloid angiopathy ( hccaa) and other neurodegenerative disorders associated with aberrant amyloid deposits
CN111458517B (zh) *	2020-03-13	2022-08-16	深圳大学	Selenof作为阿尔茨海默病药物靶点的应用
PL440896A1 (pl)	2022-04-11	2023-10-16	Uniwersytet Gdański	Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT397200B (de) *	1988-06-03	1994-02-25	Birkmayer Joerg Ddr	Verwendung von selenmethionin zur herstellung eines arzneimittels
GB9001121D0 (en) *	1990-01-18	1990-03-21	Efamol Holdings	Efa compositions and therapy
US5221545A (en)	1992-03-09	1993-06-22	Abbott Laboratories	Method of providing selenium in a nutritional product
DE4413839C1 (de) *	1994-04-21	1995-10-19	Fritz Koch Pharma Gmbh Dr Med	Kombinationspräparat
JPH09323939A (ja) *	1996-06-03	1997-12-16	R T Ee Assoc Kk	抗痴呆剤
JP2000516606A (ja) *	1996-08-13	2000-12-12	ピー・エヌ・ゲロリマトス・ソシエテ・アノニム	アルツハイマー病の処置用医薬組成物の製造におけるキレート化剤クリオキノールの使用
US6197295B1 (en)	1996-09-25	2001-03-06	Viva America Marketing Corporation	Dietary supplementation with, and methods for administration of yeast-derived selenium product
WO1998052560A1 (en) *	1997-05-21	1998-11-26	Sloan-Kettering Institute For Cancer Research	Method for increasing the concentration of ascorbic acid in brain tissues of a subject
JPH11199599A (ja) *	1997-12-09	1999-07-27	Adriel Dell Calpio Carlos	補体活性阻害性ペプチドおよび抗補体剤
FR2774596B1 (fr) *	1998-02-11	2000-03-17	Rhone Poulenc Rorer Sa	Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
WO2000012102A1 (en) *	1998-08-31	2000-03-09	Proteotech, Inc.	Blended compositions for treatment of alzheimer's disease and other amyloidoses
ATE362486T1 (de) *	1999-04-06	2007-06-15	Univ California	Menschliche, für neurogenin 3 kodierende nukleotidsequenzen
CA2325041A1 (en) *	2000-11-17	2002-05-17	Eddie Lo	Ultra-vit. plus
DE10158180A1 (de) *	2001-11-28	2003-09-11	Biovision Ag	Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
JP4666567B2 (ja) *	2001-12-07	2011-04-06	ジェロン・コーポレーション	ヒト胚幹細胞由来の膵島細胞
GB0202900D0 (en) *	2002-02-07	2002-03-27	Laxdale Ltd	Novel formulations of drugs
DK174835B1 (da) *	2002-03-15	2003-12-15	Pharma Nord Aps	Selengærprodukt, fremgangsmåde til fremstilling af et selengærprodukt samt anvendelse af produktet til fremstilling af en fødevare, et kosttilskud, eller et lægemiddel
CN1403017A (zh) *	2002-10-24	2003-03-19	田轩	富硒魔芋绿茶保健食品
US6911550B2 (en)	2003-02-21	2005-06-28	Zinpro Corporation	Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
CN1440665A (zh) *	2003-04-01	2003-09-10	宁夏长宁实业（集团）有限公司乳业分公司	富含硒及超氧化物歧化酶乳制品及其生产方法
JP2004344079A (ja) *	2003-05-23	2004-12-09	Sceti Co Ltd	チャーガを含有する健康補助食品
CA2532207A1 (en) *	2003-07-11	2005-07-21	Myriad Genetics, Inc.	Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20050069594A1 (en)	2003-08-11	2005-03-31	Jan Lubinski	Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
UY28650A1 (es) *	2003-12-05	2005-02-28	Forest Laboratories	Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CN1569123A (zh) *	2004-04-30	2005-01-26	成进学	用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺

2005
- 2005-10-28 CN CN201210286669.2A patent/CN102764279B/zh active Active
- 2005-10-28 TW TW094138021A patent/TWI319708B/zh active
- 2005-10-28 AU AU2005227420A patent/AU2005227420B2/en active Active
- 2005-10-28 JP JP2005315498A patent/JP4753683B2/ja active Active
- 2005-10-28 CN CN2005101217948A patent/CN101073584B/zh active Active
- 2005-11-07 EP EP05024235A patent/EP1774972B1/en active Active
- 2005-11-07 RS RS20120216A patent/RS52257B/en unknown
- 2005-11-07 ES ES05024235T patent/ES2382334T3/es active Active
- 2005-11-07 PL PL06007443T patent/PL1779858T3/pl unknown
- 2005-11-07 EP EP06007442A patent/EP1779857A1/en not_active Withdrawn
- 2005-11-07 SI SI200531521T patent/SI1774972T1/sl unknown
- 2005-11-07 PT PT60074432T patent/PT1779858E/pt unknown
- 2005-11-07 PL PL05024235T patent/PL1774972T3/pl unknown
- 2005-11-07 PT PT05024235T patent/PT1774972E/pt unknown
- 2005-11-07 AT AT05024235T patent/ATE547107T1/de active
- 2005-11-07 ES ES06007443T patent/ES2402365T3/es active Active
- 2005-11-07 DK DK06007443.2T patent/DK1779858T3/da active
- 2005-11-07 DK DK05024235.3T patent/DK1774972T3/da active
- 2005-11-07 EP EP06007441A patent/EP1779856A1/en not_active Withdrawn
- 2005-11-07 EP EP09005967A patent/EP2087895A1/en not_active Withdrawn
- 2005-11-07 EP EP06007443A patent/EP1779858B1/en active Active
- 2005-11-07 RS RS20130074A patent/RS52666B/en unknown
2012
- 2012-04-16 HR HRP20120337TT patent/HRP20120337T1/hr unknown
- 2012-05-28 CY CY20121100480T patent/CY1112790T1/el unknown

Also Published As

Publication number	Publication date
CN102764279A (zh)	2012-11-07
EP1779856A1 (en)	2007-05-02
ES2382334T3 (es)	2012-06-07
AU2005227420A1 (en)	2007-05-03
EP1779858A1 (en)	2007-05-02
ES2402365T3 (es)	2013-05-03
RS52257B (en)	2012-10-31
SI1774972T1 (sl)	2012-06-29
PL1779858T3 (pl)	2013-06-28
CN101073584A (zh)	2007-11-21
PT1774972E (pt)	2012-05-21
TWI319708B (en)	2010-01-21
PT1779858E (pt)	2013-04-08
TW200714277A (en)	2007-04-16
CY1112790T1 (el)	2016-02-10
DK1774972T3 (da)	2012-05-14
PL1774972T3 (pl)	2012-08-31
AU2005227420B2 (en)	2013-05-09
JP4753683B2 (ja)	2011-08-24
RS52666B (en)	2013-06-28
EP1774972A1 (en)	2007-04-18
EP1779858B1 (en)	2013-01-09
EP1779857A1 (en)	2007-05-02
ATE547107T1 (de)	2012-03-15
DK1779858T3 (da)	2013-02-04
CN102764279B (zh)	2015-04-01
CN101073584B (zh)	2012-10-10
EP1774972B1 (en)	2012-02-29
JP2007106732A (ja)	2007-04-26
EP2087895A1 (en)	2009-08-12

Publication	Publication Date	Title
HRP20120337T1 (hr)	2012-05-31	Korištenje seleno-kvasaca u liječenju alzheimerove bolesti
Zhao et al.	2012	Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons
Liobikas et al.	2011	Uncoupling and antioxidant effects of ursolic acid in isolated rat heart mitochondria
Jaganathan et al.	2013	Events associated with apoptotic effect of p-Coumaric acid in HCT-15 colon cancer cells
Cao et al.	2016	Neuroprotective effects of syringic acid against OGD/R-induced injury in cultured hippocampal neuronal cells
Su et al.	2011	Protective effects of grape seed procyanidin extract against nickel sulfate-induced apoptosis and oxidative stress in rat testes
Selvam et al.	2013	Lycopene in the management of oral submucous fibrosis
CO6400186A2 (es)	2012-03-15	Tabletas de acetato de ulipristal
Buch et al.	2012	Neuroprotective activity of Cymbopogon martinii against cerebral ischemia/reperfusion-induced oxidative stress in rats
Kou et al.	2017	Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells
Jiang et al.	2016	Alantolactone induces apoptosis of human cervical cancer cells via reactive oxygen species generation, glutathione depletion and inhibition of the Bcl-2/Bax signaling pathway
Marouf et al.	2011	Free radical scavenging activity of silibinin in nitrite-induced hemoglobin oxidation and membrane fragility models
Gao et al.	2014	Tacrine induces apoptosis through lysosome-and mitochondria-dependent pathway in HepG2 cells
Said et al.	2012	Hesperidin attenuates brain biochemical changes of irradiated rats
MA35342B1 (fr)	2014-08-01	Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
JP2012236834A5 (zh)	2013-01-24
Atsumi et al.	2001	Reactive oxygen species generation and photo-cytotoxicity of eugenol in solutions of various pH
Kaur et al.	2017	Evaluation of anti-inflammatory effects of systemically administered curcumin, lycopene and piperine as an adjunct to scaling and root planing: A clinical study
Yedjou et al.	2013	Vernonia amygdalina—induced growth arrest and apoptosis of breast cancer (MCF-7) cells
Echiburú-Chau et al.	2014	The selective cytotoxicity elicited by phytochemical extract from Senecio graveolens (Asteraceae) on breast cancer cells is enhanced by hypoxia
BRPI0511710A8 (pt)	2017-12-19	Comprimido mastigável, sugável e deglutível contendo cálcio
Wang et al.	2013	Oligomeric proanthocyanidin protects retinal ganglion cells against oxidative stress-induced apoptosis
Tahani et al.	2018	Effect of Camellia sinensis plant on decreasing the level of halitosis: A systematic review
Asghari et al.	2022	Olea europaea L.(olive) leaf extract ameliorates learning and memory deficits in streptozotocin-induced diabetic rats
San Miguel et al.	2011	Use of antioxidants in oral healthcare